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Abstract: Immobilization of transaminases creates promising biocatalysts for production of chiral
amines in batch or continuous-flow mode reactions. E. coli cells containing overexpressed
transaminases of various selectivities and hollow silica microspheres as supporting agent were
immobilized by an improved sol-gel process to produce immobilized transaminase biocatalysts with
suitable stability and mechanical properties for continuous-flow applications. The immobilized
cell-based transaminase biocatalyst proved to be durable and easy-to-use in kinetic resolution
of four racemic amines 1a–d. The batch and continuous-flow mode kinetic resolutions with
transaminase biocatalyst of opposite stereopreference provided access to both enantiomers of
the corresponding amines. By using the most suitable immobilized transaminase biocatalysts, this
study describes the first transaminase-based approach for the production of both pure enantiomers of
1-(3,4-dimethoxyphenyl)ethan-1-amine 1d.
Keywords: stereoselective biocatalysis; transaminase; kinetic resolution; flow chemistry; sol-gel;
whole-cell immobilization
1. Introduction
Enantiopure amines are essential chiral building blocks for the synthesis of a wide variety of active
pharmaceutical ingredients. Chemical synthesis of these compounds usually employs transition metal
catalysts of relatively high toxicity, and may require harsh reaction conditions. In recent years, there has
been a growing interest in transaminases (TAs), which offer a sustainable alternative to these synthetic
chemical processes [1–3]. Transaminases have been successfully used in the preparation of several
pharmaceutically relevant compounds, like 3-aryl-γ-aminobutyric acid derivatives [4], sitagliptin [5]
and valinol [6].
Transaminases can be applied for separation of the enantiomers from their racemates in kinetic
resolution (KR) with a maximum of 50% yield, or for conversion of a prochiral carbonyl compound to a
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chiral amine in asymmetric synthesis with a theoretical yield of 100%. Although asymmetric synthesis
could provide higher yields, it usually suffers from disfavored reaction equilibrium [7]. Furthermore,
the costs of enzyme production indicates the need for biocatalyst recovery in an economically viable
process [8]. These are the most significant difficulties hindering the widespread industrial application
of transaminases. Several strategies have been developed to overcome the difficulties arising from the
disfavored reaction equilibrium in asymmetric synthesis with TAs, such as the removal of products by
extraction [9], by evaporation [10] or by coupled cascade reactions [11,12]. The overall efficiency of the
KR process may be enhanced by recycling the formed ketone to racemic amine by a proper reductive
amination method [13]. Although these solutions work well in batch reactions, for the sustainable,
industrial production of enantiopure amines the intensification possibilities offered by immobilized TA
biocatalysts and by the continuous-mode operations are needed [1]. This trend is indicated by the
successful applications of TAs in continuous-flow reactors which have been developed in the past
years [14–23].
A wide range of immobilization methods for transaminases have been reported over the last
couple of years. Transaminases have been successfully immobilized by using different kinds
of carriers, such as polymeric resins [7,16,23], functionalized cellulose [21], chitosan [24–26],
inorganic-based nanoflowers [27,28], macrocellular silica monoliths [19], MnO2 nanorods [29] or
porous glass metal affinity supports [22]. In addition to immobilization of TAs in their isolated
and fully or partially purified form, the entrapment of cell-free extracts, or even whole cells with
comprising TA activity in different sol-gel matrices [14,30,31] proved to be an excellent approach
to prepare high-performance and stable immobilized biocatalysts. In many cases, utilization of
whole cells over enzyme solutions is advantageous due to the lower production costs, increased
stability and easier handling [32]. Immobilized transaminases have been successfully employed
in the preparation of several enantiopure compounds, such as 1-phenoxypropane-2-amine [33],
3-amino-1-Boc-piperidine [34], 1-methyl-3-phenylpropylamine [23,26] and mexiletine [16].
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Scheme 1. Continuous-flow kinetic resolution of primary amines rac-1a–d with immobilized whole-cell
transaminase biocatalysts.
This study aimed at the preparation of robust, stereoselective TA biocatalysts capable of operating
under continuous-flow conditions to produce enantiopure amines. A promising sol-gel-based
whole-cell immobilization method has already been applied in a previous work of our group for
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the transaminase from Chromobacterium violaceum expressed in E. coli [14]. Hereby we report the
immobilization of further transaminases with different enantioselectivity and substrate specificity.
The immobilized cells proved to be easy-to store, cheap and durable biocatalysts, and were applied
successfully in the continuous kinetic resolution of racemic amines (Scheme 1).
2. Results and Discussion
2.1. Immobilized Recombinant Whole-Cells as Transaminase Biocatalysts
In this study, six different transaminase-expressing E. coli whole-cells were immobilized by an
improved sol-gel entrapment method including three (S)-selective TAs [from Vibrio fluvialis (VfS-TA),
Arthrobacter sp. (ArS-TA) and a mutated variant of Chromobacterium violaceum TA (CvS-TAm)] and three
(R)-selective TAs [from Aspergillus terreus (AtR-TA), Arthrobacter sp. (ArR-TA) and its mutated variant
(ArR-TAm)].
A multistep immobilization protocol was used to prepare the whole-cell TA biocatalysts (Figure 1).
First, a silica sol was formed by the acid-catalyzed hydrolysis of tetraethyl orthosilicate (TEOS). After
the sol formation, a suspension consisting of E. coli cells containing the recombinant transaminase and
hollow silica microspheres as supporting aid was added to the sol. The silica microspheres possess
excellent properties for the adsorption of whole cells due to their high specific surface area grafted with
aminoalkyl and vinyl functions. Upon standing the formed mixture of the cells and microspheres in
silica sol, gelation occurred. Aging of the formed sol-gel was performed at 4 ◦C for 2 days. Finally, the
formed sol-gel powder was gently crushed and washed with water. The immobilized whole-cell TA
biocatalyst were then dried at room temperature for 1 day, then stored at 4 ◦C in the form of powder.
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Figure 1. Process for immobilization of transaminase-containing recombinant E. coli cells. The
immobilized transaminase (TA) biocatalysts can be pplied both in batch (e.g., shake vials) and in
continuous-flow operations (e.g., packed bed reactors).
The immobilization method applied in this study combines the advantages of cell-adsorption and
sol-gel ntrapment. The silica micros h res provide the g od m chanical properties of the biocatalyst,
while the entrap ing silica matrix affo d the high immobilizati n yield (~100% of the cells were
retained [14]; ~0.9 g of dry TA biocatalyst could be produced from 1 g of wet cells). The immobilization
could be scaled up from g scale to 10 g scale without any noticeable problem. The immobilized
TA-containing whole-cells proved to be easy to produce, reproduc ble and robus biocatalysts operating
re arkably well in continuous-flow sy tems. Despite of the appa ently ha sh conditions during the
immobilization (strong acidic environment, drying at atmosph ric pr sur and room temperature),
the transaminase containing cells remained catalytically active in their air-dried, w ll-preserved
imm bilized form fo many mo ths. Activity yield could be determined by comparison of the activity
data with the w t cells vs. with the im obilized TA biocatalysts. At th optimum pH (~7.5) activity
yields in the rang of 80–105% could be observed for the six immobilized TA biocatalysts (see Section 3
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and Figure S18 in the Supplementary Materials). The immobilized biocatalysts retained 95% activity
after storing for 6 months in refrigerator (determined by testing the kinetic resolution of rac-1c at 24 h
reaction time).
2.2. Kinetic Resolution of Amines with Immobilized Transaminases
2.2.1. Shake Vial Screening of Immobilized Transaminases in Kinetic Resolution of Amines rac-1a–d
The immobilized TA biocatalysts were tested in the kinetic resolution of amines rac-1a–d with an
aim to choose the best performing (S)- and the best performing (R)-selective transaminase biocatalyst
for further testing in continuous-flow mode KRs. While amines rac-1a–c were frequently used as
model substrates for transaminases, to our best knowledge the KR of rac-1d has never been tested
with transaminases before. The only examples of biocatalytic approaches to the enantiomers of 1d are
lipase-catalyzed kinetic resolution [35] or dynamic kinetic resolution [36]. The results of the screening
experiments are shown in Table 1.
Table 1. Shake vial screening of immobilized TA biocatalysts in kinetic resolution of amines rac-1a–d.
Entry TA a
1a b 1b b 1c b 1d b
c (%) c ee (%) c c (%) c ee (%) c c (%) c ee (%) c c (%) c ee (%) c
1 ArS-TA 53 98.1 (R) 51 89.6 (R) 44 79.9 (R) 51 >99.8 (R)
2 VfS-TA 50 64.5 (R) 47 66.8 (R) 39 65.0 (R) 13 13.1 (R)
3 CvS-TAm 38 39.3 (R) 44 76.2 (R) 17 21.1 (R) 23 26.4 (R)
4 AtR-TA 51 97.0 (S) 48 86.4 (S) 42 72.9 (S) 51 >99.8 (S)
5 ArR-TA 57 99.7 (S) 49 90.4 (S) 35 53.7 (S) 36 50.1 (S)
6 ArR-TAm 47 97.5 (S) 33 29.9 (S) 21 27.3 (S) 15 15.5 (S)
a Source organism and former abbreviations of the transaminases: ArS-TA: Arthrobacter sp., (S)-selective
(ArS-ωTA [37]); VfS-TA: Vibrio fluvialis (Vf-ωTA [38]); CvS-TAm: Chromobacterium violaceum, mutant
(Cv-ωTAW60C [23,39]); ArR-TA: Arthrobacter sp., (R)-selective (ArR-ωTA [40]); AtR-TA: Aspergillus terreus (AT-ωTA
[40]); ArR-TAm: Arthrobacter sp. (ArRmut11-ωTA [40]). b Reagents and conditions in 5 mL reaction: amine rac-1a–d
(30 mM), immobilized transaminase (100 mg), sodium pyruvate (22.5 mM), pyridoxal-5′-phosphate monohydrate
(PLP, 0.3 mM), phosphate buffer (pH 7.5, 100 mM), 30 ◦C, 24 h. c Conversion (c) of rac-1a–d to the corresponding
ketone 2a–d and enantiomeric excess (ee) for the residual amine (R)-1a–d or (S)-1a–d were determined after
derivatization with Ac2O by gas chromatography (GC) on chiral stationary phase.
The immobilized TA biocatalysts were effective for the KRs of the investigated amines rac-1a–d in
batch reactions. Regarding the (S)-selective TAs, CvS-TAm had the lowest catalytic activity, VfS-TA
and ArS-TA were able to catalyze the conversion of the amines to the corresponding ketone with
conversions similar to each other. However, ArS-TA had better enantioselectivity for all of the
investigated substrates than the other two (S)-selective TAs, with superior performance in the KR
of rac-1d. Among the investigated (R)-selective TAs, ArR-TAm (the mutant variant of ArR-TA) had
the lowest overall activity, since this variant was engineered for the bioconversion of large, bulky
substrates [5]. ArR-TA and AtR-TA performed comparably in the KRs of the tested amines rac-1a–d.
Nonetheless, in case of the KR of rac-1d, the activity of AtR-TA exceeded the one of ArR-TA. Although
lower conversions (c) from rac-1c–d were reached with ArR-TA than the corresponding ones with
AtR-TA, the values of enantiomeric ratio (E)—which could be calculated from the corresponding
conversion (c)-enantiomeric excess (ee) values [41]—indicated highly enantiomer selective KRs. The
performance of CvS-TAm could be evaluated similarly; the conversion (c)-enantiomeric excess (ee)
values experienced in KRs from rac-1b–d indicated highly enantiomer selective transformations at
lower conversion rates. Based on these results, the (S)-selective ArS-TA and the (R)-selective AtR-TA
biocatalysts were selected for the further continuous-flow experiments.
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2.2.2. Kinetic Resolution of Amines rac-1a–d with Immobilized TA Biocatalysts in
Continuous-Flow Mode
The conditions for the kinetic resolution of amines 1a–d in continuous-flow mode were optimized
using ArS-TA and AtR-TA. First, the immobilized whole-cell TA biocatalyst-filled columns were fed
with the racemic amine (either of the rac-1a–d)-containing solution at 7.5 mM substrate concentration by
varying the flow rates from 40 to 100 µL min−1. If even at the highest flow rate (100 µL min−1; limited by
achievable pressure) the 50% theoretical conversion was achieved while maintaining high enantiomeric
excess (>98%), further experiments with increased substrate concentrations were performed. The best
conditions found in this way are displayed in Table 2 for ArS-TA and in Table 3 for AtR-TA.
Table 2. Production of (R)-1a–d by kinetic resolution of rac-1a–d with whole-cell immobilized ArS-TA
under optimized conditions in continuous-flow mode a.
Entry Substrate Substrate Conc. (mM) Flow Rate (µL min−1) Conversion (%) ee(R)-1 (%)
1 rac-1a 7.5 100 50 99.1
2 rac-1b 20 100 51 >99.8
3 rac-1c 50 50 50 >99.8
4 rac-1d 20 40 53 99.1
a For reaction details see Section 3.5.1.
Table 3. Production of (S)-1a–d by kinetic resolution of rac-1a–d with whole-cell immobilized AtR-TA
under optimized conditions in continuous-flow mode a.
Entry Substrate Substrate Conc. (mM) Flow Rate (µL min−1) Conversion (%) ee(S)-1 (%)
1 rac-1a 7.5 100 52 99.2
2 rac-1b 7.5 50 51 >99.8
3 rac-1c 7.5 50 49 98.8
4 rac-1d 10 60 b 53.5 99.2
a For reaction details see Section 3.5.1. b Two columns connected serially.
Similar to the KRs performed in batch mode, the immobilized ArS-TA biocatalyst exhibited
excellent activity and good to high enantiomer selectivity in continuous-flow mode KRs of the
racemic amines rac-1a–d. While the KR of rac-1a with the ArS-TA biocatalyst could be performed
with 50% conversion at the lowest selected substrate concentration (7.5 mM), full conversion of the
(S)-enantiomers could be achieved at significantly higher substrate concentrations of rac-1b and rac-1c
resulting in the (R)-1b and (R)-1c with excellent ee values. The enantiomer selectivity of the ArS-TA
biocatalyst towards rac-1d was less pronounced, which was indicated by several runs with conversion
values well over 50% indicating that significant amount of (R)-1d was also transformed. However, by
raising the flow rate, which resulted in decreased residence time, a proper conversion of 53% from
rac-1d could be achieved with good enantiomeric excess of the residual (R)-1d (ee(R)-1d = 99.1%).
When the (R)-selective immobilized whole-cell AtR-TA was employed as biocatalyst, almost perfect
kinetic resolution of amines rac-1a–c could be performed with full consumption of the (S)-enantiomer
(Table 3: c = 49–52% from rac-1a–c); however, only at relatively low substrate concentrations (7.5 mM of
rac-1a–c). In the case of rac-1d the conversion could not reach 50% in a single column even at the lowest
investigated substrate concentration (7.5 mM of rac-1d); consequently, the complete KR of rac-1d had
to be performed by means of two serially connected AtR-TA biocatalyst-filled columns. Similar to the
ArS-TA, a conversion of rac-1d exceeding significantly the 50% (R)-enantiomer content was observed
in the AtR-TA biocatalyst-catalyzed KRs at lower flow rates (≤50 µL min−1), indicating a decreased
degree of enantiomer selectivity as compared to the ones in KRs of the other three amines rac-1a–c.
Nevertheless, increasing the flow rate of the continuous-flow KR of rac-1d to 60 µL min−1 enabled a
process with proper conversion (c = 53.5%) and enantiomeric excess (ee(S)-1d = 99.2%), which was also
suitable for performing preparative scale experiments.
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2.2.3. Preparative Scale Kinetic Resolutions of rac-1d in Continuous-Flow Mode
To demonstrate the synthetic applicability of the selected novel immobilized whole-cell (S)- and
(R)-selective TA biocatalysts, the KR of 1d was performed on a preparative scale in continuous-flow
mode (Figure 2). The pure enantiomers of the drug-like compound 1d are potential building blocks for
several reported drug candidates: Akincioglu [42] published a study of novel sulfamoyl carbamates
and sulfamides as potential carbonic anhydrase and acetylcholine esterase inhibitors, while Kerr [43]
studied the employment of N-(phenylpropyl)-1-arylethylamines as allosteric modulators of GABAB
receptors with good results. These studies indicate the importance of efficient methods for production
of the enantiomers amines like 1d. The preparative scale continuous-flow KRs of rac-1d performed
with the most efficient (S)-selective and (R)-selective immobilized whole-cell TA biocatalysts (ArS-TA
and AtR-TA, respectively) resulted in efficient production of either (S)-1d or (R)-1d in good isolated
yields and excellent enantiomeric excess (Table 4)
Table 4. Preparative scale production of either (S)-1d or (R)-1d by kinetic resolution of rac-1d in
continuous-flow mode.
Transaminase Product ee (%) Yield (%) Space Time Yield (mg cm−3 day−1)
ArS-TA (R)-1d a 99.1 (R) 45 115
AtR-TA (S)-1d b 99.2 (S) 44 42.2
a 20 mM rac-1d, 40 µL min−1. b 10 mM rac-1d, 60 µL min−1 with two columns.
The system with immobilized AtR-TA was stable for 21 h, producing virtually enantiopure
(S)-1d (ee(S)-1d = 99.3%) with a space time yield of 42.2 mg cm
−3 day−1 (Figure 2b). The immobilized
ArS-TA proved to be more durable, with more than 2 days of stable operation while producing
apparently enantiopure (R)-1d (ee(R)-1d 99.1%) with an outstanding space time yield of 115 mg cm
−3
day−1 (Figure 2a).
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Figure 2. Long-term stability of the most efficient (S)-selective (ArS-TA) and (R)-selective (AtR-TA)
immobilized TA biocatalysts in preparative scale continuous-flow kinetic resolution of rac-1d with
(a) immobilized ArS-TA; and (b) immobilized AtR-TA [conversion (×), ee(R)-1d () and ee(S -1d ()].
Since the enzymes in this study were immobilized as whole-cell preparations, the transaminases
themselves could not be stabilized by multipoint fixation to a support by this method. Several
physiological processes could account to the observed loss of activity in the long term, e.g.,
the degradation of proteins, or the dissociation of the enzyme monomers from the heterodimeric
structure inside the intracellular space.
3. Materials and Methods
3.1. Materials
Except where otherwise stated, all chemicals and starting materials were purchased from
Sigma-Aldrich (St. Louis, MO, USA) or Alfa Aesar Europe (Karlsruhe, Germany). MAT540
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(MATSPHERE™ SERIES 540-hollow silica microspheres etched with aminoalkyl and vinyl functions,
with an average particle diameter of 10 µm) was purchased from Materium Innovations (Granby, QC,
Canada). The procedure for the synthesis of rac-1d is described in the Supporting Materials (Section S2.1).
3.2. Recombinant Transaminase Production
Production of ArS-TA [37] and VfS-TA [38] was achieved in E. coli BL21(DE3) containing the
recombinant pASK-IBA35+ plasmid with the gene of the given TA. LB-Car medium (5 mL; LB medium
containing carbenicillin, 50 mg L−1) was inoculated with one fresh colony from an overnight LB-Car
agar plate and cells were grown overnight in shake flask (37 ◦C, at 200 rpm). LB medium (0.5 L) in a
2 L flask was inoculated with seed culture (2 mL) and cells were grown at 37 ◦C, 200 rpm until the
OD640 reached 0.8 (approx. 4 h). For induction, tetracycline solution (20 µL, 5 mg mL−1 tetracycline in
ethanol) was added and the culture was shaken for further 16 h at 25 ◦C, 200 rpm. The cells were then
harvested by centrifugation (15,000 g, 4 ◦C, 20 min).
Production of AtR-TA [40], ArR-TA [40], ArR-TAm [40] and CvS-TAm [39] was achieved in E. coli
BL21(DE3) containing the recombinant pET21a plasmid with the gene of the given TA. LB-Car medium
(5 mL; LB medium containing carbenicillin, 50 mg L−1) was inoculated with one fresh colony from
an overnight LB-Car agar plate and cells were grown overnight in shake flask (37 ◦C, at 200 rpm).
Autoinduction medium (0.5 L: Na2HPO4, 6 g L−1; KH2PO4, 3 g L−1; tryptone, 20 g L−1; yeast extract,
5 g L−1; NaCl, 5 g L−1; glycerol, 7.56 g L−1; glucose, 0.5 g L−1; lactose, 2 g L−1 [44]) in a 2 L flask was
inoculated with seed culture (2 mL) and was shaken for 16 h at 25 ◦C, 200 rpm. The cells were then
harvested by centrifugation (15,000× g, 4 ◦C, 20 min).
3.3. Immobilization of Transaminase-Expressing Whole-Cells
First a silica sol was prepared by addition of TEOS (14.4 mL) to a solution containing 0.1 M
HNO3 (1.3 mL) and distilled water (5 mL) followed by sonication of the resulted mixture for 5 min
at room temperature (Emag Emmi 20HC Ultrasonic Bath, 45 kHz) and keeping the mixture at 4 ◦C
for 24 h. Next, a cell paste suspension (10 g of paste of the centrifuged TA-expressing E. coli cells,
suspended in 30 mL of 0.1 M phosphate buffer, pH 7.5) was mixed with a suspension of MAT540
support (3 g, suspended in 30 mL of 0.1 M phosphate buffer, pH 7.5) and shaken intensively until
become homogeneous (Technokartell Test Tube Shaker Model T3SK, 40 Hz, room temperature, 5 min).
Finally, the homogenized supported cell suspension was mixed with the silica sol and the resulted
mixture was shaken intensively (Technokartell Test Tube Shaker Model T3SK, 40 Hz, room temperature,
5 min). Gelation occurred within 30 min at room temperature, followed by aging the gel at 4 ◦C for 48
h in an open dish. The crude immobilized TA biocatalyst was washed with distilled water (2 × 15 mL,
100 mM, pH 7.5), dried at room temperature (24 h), and stored at 4 ◦C to yield ~9 g of immobilized TA
biocatalyst. The immobilized whole-cell TA biocatalysts could be stored in the refrigerator for months
without significant loss of the original TA activity.
3.4. Kinetic Resolution of Amines rac-1a–d with the Immobilized TA Biocatalysts in Batch Mode
The immobilized TA biocatalyst (100 mg) was suspended in phosphate buffer (5 mL, 100 mM,
pH 7.5) containing the racemic amine (rac-1a–d, 30 mM), sodium pyruvate (22.5 mM) and
pyridoxal-5′-phosphate monohydrate (PLP, 0.3 mM) in 20 mL vials. The reaction mixture was
shaken on an orbital shaker (600 rpm) at 30 ◦C for 24 h. To the samples taken from the reaction mixture
(100 µL) sodium hydroxide (100 µL, 1 M) was added, followed by extraction with ethyl acetate (800 µL).
Derivatization of the amines was performed by the addition of acetic anhydride (10 µL, 60 ◦C, 1 h), then
the organic phase was dried over Na2SO4. Samples were analyzed by gas chromatography {analysis
was performed on Agilent 4890 equipment with FID detector and Hydrodex β-6TBDM column [25 m
× 0.25 mm × 0.25 µm film with heptakis-(2,3-di-O-methyl-6-O-t-butyldimethylsilyl)-β-cyclodextrine;
Macherey & Nagel] using H2 carrier gas (injector: 250 ◦C, detector: 250 ◦C, head pressure: 12 psi, split
ratio: 50:1)}. For details see Supplementary Materials Table S1.
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3.5. Biotransformations with the Immobilized TA Biocatalysts in Continuous-Flow Mode
The kinetic resolutions of rac-1a–d with the novel immobilized TA biocatalysts in continuous-flow
mode were performed in a laboratory scale flow reactor built from a Knauer Azura P4.1S isocratic
HPLC pump attached to SynBioCart™ columns (SynBiocat, Budapest, Hungary; stainless steel outer
and PTFE inner tube, inner diameter: 4 mm; total length: 70 mm; packed length: 65 mm; inner volume:
0.816 mL) filled with the immobilized whole-cell biocatalyst (ArS-TA or AtR-TA biocatalyst, filling
weights: 375 ± 12 mg a column) in an in-house made aluminum metal block column holder with
precise temperature control. The columns were sealed by filter membranes made of PTFE [Whatman®
Sigma-Aldrich, WHA10411311, pore size 0.45 µm]. The sealing elements were made of PTFE.
3.5.1. Kinetic Resolution of Racemic Amines rac-1a–d with Immobilized TA Biocatalysts in
Continuous-Flow Mode
Kinetic resolutions of rac-1a–d in continuous-flow mode were performed in SynBioCart™ columns
filled with the immobilized TA biocatalysts (ArS-TA or AtR-TA biocatalyst). The racemic amine
(rac-1a–d; 7.5–50 mM) was dissolved in phosphate buffer (20 mL, 100 mM, pH 7.5) containing sodium
pyruvate (0.75 equivalent to the racemic amine) and PLP (0.3 mM). The biocatalyst-filled column
was pre-washed by phosphate buffer (50 µL min−1 for 60 min) followed by pumping the substrate
solution through the column at various flow rates (ranging from 40 µL min−1 to 100 µL min−1) at 30 ◦C.
Samples were taken in triplicate after reaching the stationary phase, and analyzed (after extraction
and derivatization as described above) by GC as described earlier. The standard deviation (SD) of
measurements in triplicate did not exceed 1.5% of the mean value; therefore, SD values were not
indicated in the Tables.
3.5.2. Preparative Scale Production of (S)- and (R)-1-(3,4-Dimethoxyphenyl)ethan-1-Amine [(S)-1d and
(R)-1d] by Kinetic Resolution with Immobilized TA Biocatalysts in Continuous-Flow Mode
Kinetic resolutions of rac-1d in continuous-flow mode for preparative purposes were performed
as described above operating the immobilized TA biocatalyst-filled (ArS-TA or AtR-TA biocatalyst)
SynBioCart™ columns for longer periods. The residual amine [(S)-1d or (R)-1d] was isolated from
the effluent during stationary phase of the operation. The pH of the collected effluent was adjusted
to 1 by cc. HCl, and the forming ketone 2d was removed by extraction with dichloromethane
(3 × 40 mL). After removal of the ketone 2d, the pH of the aqueous phase was adjusted to 10 by
addition of ammonium hydroxide (25%) and the residual amine [(S)-1d or (R)-1d] was extracted with
dichloromethane (3 × 40 mL). The unified organic phases were extracted with brine (30 mL), dried over
Na2SO4 and concentrated in vacuum to yield the product amine [(R)-1d: 45% yield (227.1 mg, ee(R)-1d
99.1%, [α]D27 = +21.5 (c 1, EtOH)) from a 58 h long run at 40 µL min−1 flow rate; or (S)-1d: 44% yield
(60.3 mg, ee(S)-1d 99.2%, [α]D
27 = −21.5 (c 1, EtOH)) from a 21 h long run at 60 µL min−1 flow rate)].
4. Conclusions
In this study, immobilization of six transaminases—involving three (S)-selective and three
(R)-selective transaminases—was investigated in their recombinant E. coli whole-cell forms together
with hollow silica microspheres as support by entrapment in a sol-gel system. The immobilized
whole-cell TA biocatalysts were able to catalyze the kinetic resolution of various amines efficiently in
batch and in continuous-flow mode. The easy-to-use immobilized TA biocatalysts showed enhanced
storage-stability and proved to be stable even in long-term continuous processes. To the best of
our knowledge, this process is the first example for the transaminase-based production of the pure
enantiomers of the drug-like 1-(3,4-dimethoxyphenyl)ethan-1-amine (S)-1d and (R)-1d. Our results
demonstrate how continuous-flow operations can contribute to sustainable production of essential
chiral building blocks with the aid of biocatalysis.
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Figure S1: 1H-NMR spectrum of rac-1d, Figure S2: 13C-NMR spectrum of rac-1d, Figure S3: FT-IR spectrum of
rac-1d, Figure S4: GC chromatogram of rac-1a and 2a, Figure S5: GC chromatogram of rac-1b and 2b, Figure S6:
GC chromatogram of rac-1c and 2c, Figure S7: GC chromatogram of rac-1d and 2d, Figure S8: GC chromatogram
of KR from rac-1d, Figure S9: GC chromatogram of (R)-1d after working up the KR reaction mixture, Figure S10:
1H-NMR spectrum of (R)-1d, Figure S11: 13C-NMR spectrum of (R)-1d, Figure S12: FT-IR spectrum of (R)-1d.,
Figure S13: GC chromatogram of KR from rac-1d, Figure S14: GC chromatogram of (S)-1d after working up the
KR reaction mixture, Figure S15: 1H-NMR spectrum of (R)-1d, Figure S16: 13C-NMR spectrum of (R)-1d, Figure
S17: FT-IR spectrum of (S)-1d, Figure S18: pH dependence of the transaminase containing wet E. coli cells and the
immobilized TA biocatalysts, Table S1: GC data of reference substrates and products.
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